It is important to note, however, that while FcRγ ITAM domains effectively activate macrophage functions, CD3ζ-based CARs have been reported to demonstrate superior tumor cell killing compared to FcRγ-based CARs. This evidence concerns the gene FCER1G and neoplasm.